LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

Publication of the Three-Year Follow-Up Results of FIM Clinical Study of IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the three-year follow-up of the feasibility of FIM clinical study (the "**Study**") on the Group's self-developed IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System ("**IBS® Coronary Scaffold**" or the "**Product**") has been successfully completed, and the results were published online by Professor Gao Runlin's team at Fuwai Hospital, Chinese Academy of Medical Sciences, on the authoritative international medical journal EuroIntervention on 10 April, 2023.

The Study was conducted in Fuwai Hospital, Chinese Academy of Medical Sciences in 2018, with Professor Gao Runlin as the principal investigator (PI). In the Study, participants were randomly assigned to two cohorts, with cohort 1 completing six months and two years of imaging follow-up, and cohort 2 completing one year and three years of imaging follow-up, with preliminary positive results. The completion of three-year follow-up of the Study indicates that the commercialization process of this innovative product is continuously and steadily advancing.

The IBS® Coronary Scaffold operates in the same way as the metal permanent stents, without compulsory PSP and slow dilatation. All stents in the Study were successfully implanted in the patients, without surgical complications, and the device, lesion and clinical success rates were all 100%. Clinical data shows that the target lesion failure rate ("TLF") after six months of stent implantation is only 2.2%, while the TLF after one, two, and three years of implantation remains stable at 6.7%, with no deaths, myocardial infarction, or thrombotic events occurring throughout the follow-up period. Meanwhile, the OCT analysis results showed that the neointimal coverage rate after six months of stent implantation was as high as 99.8%, and reached 100% one year later. Preliminary results suggest that IBS® Coronary Scaffold has a good interim safety profile in simple primary coronary lesions.

At the same time, there were no stenotic changes in the lumen during the three-year follow-up period and no long-term acquired malapposition during the degradation of the Product. In-segment late luminal loss (LLL) was 0.25±0.26 mm at six months, 0.27±0.45 mm at one year, 0.27±0.35 mm at two years, and 0.21±0.38 mm at three years. In addition, the lumen area of IBS® Coronary Scaffold continued to expand after six months of implantation, steadily increasing from 7.22mm^2 to 8.03mm^2 after three years of implantation, which was significantly different from the lumen area of other stents that continued to decrease with increasing stent implantation time. This is the expected development trend of absorbable stents and reflects the unique clinical advantages of IBS® Coronary Scaffold.

In addition, the rate of absorption of IBS® Coronary Scaffold was observed to be 82%±10% after two years of implantation and 95%±4% after three years of implantation from the Study, providing sufficient evidence that iron-based stents can be safely absorbed in humans. Iron-based fully degradable metal coronary stents show its great potential and bright prospects.

IBS® Coronary Scaffold is the world's first fully degradable iron-based absorbable coronary scaffold, as far as the Company is aware. The substrate is processed from high-purity nitrided iron pipes with high strength and plasticity, and the support wall is thin and strong. The innovative material research and unique technological path enable the Product to retain the advantages of complete specifications, superior physical properties, good biocompatibility, and simple operation of permanent metal coronary stents, as well as fully absorbable characteristics, effectively avoiding a series of long-term prognosis issues that may arise from the implantation of permanent metal stents.

The release of the three-year follow-up results of the Study further enhances the evidence-based medical evidence of this innovative product, and will also lay a solid foundation for the global development of the Product and other core products on the Company's iron-based bioabsorbable material platform. The IBS® Coronary Scaffold has completed phase II randomized controlled clinical studies with all subjects enrolled in December 2022, and its prospective, multicenter, single arm target study (i.e., phase III clinical study) is currently under clinical enrollment. With the steady advancement of follow-up clinical trials, there is expected to be more evidence-based medical evidences to further confirm the safety and effectiveness of the Product. The Company believes that when it is launched to market, IBS® Coronary Scaffold will bring unprecedented treatment for patients with coronary heart disease all over the world.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 12 April 2023

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.